Abstract
The activities of Src-family non-receptor tyrosine kinases are regulated by structural changes that alter the orientation of key residues within the catalytic domain. In this study, we investigate the effects of activation loop mutations on regulation of the lymphocyte-specific kinase Lck (p56lck). Substitution of 5–7 residues amino terminal to the conserved activation loop tyrosine (Y394) increases kinase activity and oncogenic potential regardless of regulatory C-terminal tail phosphorylation levels (Y505), while most mutations in the 13 residues carboxyl to Y394 decrease kinase activity. Phosphorylation of the C-terminal regulatory tail is carried out by the cytosolic tyrosine kinase Csk and we find that mutations upstream or downstream of Y394 or mutation of Y394 do not affect the level of Y505 phosphorylation. In addition, we report that mutations on either side of Y394 affect substrate specificity in vivo. We conclude that the high degree of conservation across the entire activation loop of Src-family kinases is critical for normal regulation of kinase activity and oncogenicity as well as substrate selection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abraham N and Veillette A. . 1990 Mol. Cell. Biol. 10: 5197–5206.
Amrein KE and Sefton BM. . 1988 Proc. Natl. Acad. Sci. USA 85: 4247–4251.
Bougeret C, Delaunay T, Romero F, Jullien P, Sabe H, Hanafusa H, Benarous R and Fischer S. . 1996 J. Biol. Chem. 271: 7465–7472.
Carrera AC, Alexandrov K and Roberts TM. . 1993 Proc. Natl. Acad. Sci. USA 90: 442–446.
Carrera AC, Borlado LR, Gonzalez-Garcia A, Roberts TM and Martinez AC. . 1995 Oncogene 10: 2379–2386.
Cartwright CA, Eckhart W, Simon S and Kaplan PL. . 1987 Cell 49: 83–91.
Cooper JA and MacAuley A. . 1988 Proc. Natl. Acad. Sci. USA 85: 4232–4236.
Eck MJ, Shoelson SE and Harrison S. . 1993 Nature 362: 87–91.
Gervais FG, Chow LML, Lee JM, Branton PE and Veillette A. . 1993 Mol. Cell. Biol. 13: 7112–7121.
Hofstra RMW, Landsvater RM, Cecchini I, Stulp RP, Stelwagen T, Luo Y, Paasini B, Hoppener JWM, van Amstel HKP, Romeo G, Lips CJM and Buys CHCM. . 1994 Nature 367: 375–376.
Hubbard SR. . 1997 EMBO J. 16: 5572–5581.
Hubbard SR, Wei L, Ellis L and Hendrickson WA. . 1994 Nature 372: 746–754.
Johnson LN, Noble MEM and Owen DJ. . 1996 Cell 85: 149–158.
Jullien P, Bougeret C, Camoin L, Bodeus M, Durand H, Disanto JP, Fischer S and Benarous R. . 1994 Eur. J. Biochem. 224: 589–596.
Kmiecik TE and Shalloway D. . 1987 Cell 49: 65–73.
Madhusudan, Trafny EA, Xuong N-H, Adams JA, Eyeck LFT, Taylor SS and Sowadski JM . 1994 Protein Sci. 3: 176–187.
Marth JD, Cooper JA, King CS, Ziegler SF, Tinker DA, Overell RW, Krebs EG and Perlmutter RM. . 1988 Mol. Cell. Biol. 8: 540–550.
Mohammadi M, Schlessinger J and Hubbard SR. . 1996 Cell 86: 577–587.
Osusky M, Taylor SJ and Shalloway D. . 1995 J. Biol. Chem. 270: 25729–25732.
Pear WS, Nolan GP, Scott ML and Baltimore D. . 1993 Proc. Nalt. Acad. Sci. USA 90: 8392–8396.
Piao X, Paulson R, Van der Geer P, Pawson T and Bernstein A. . 1996 Proc. Natl. Acad. Sci. USA 93: 14665–14669.
Piwnica-Worms H, Saunders KB, Roberts TM, Smith AE and Cheng SH. . 1987 Cell 49: 75–82.
Ruzzene M, James P, Brunati AM, Donella-Deana A and Pinna LA. . 1994 J. Biol. Chem. 269: 15885–15891.
Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A and Kuriyan J. . 1999 Mol. Cell 3: 639–648.
Sicheri F, Moarefi I and Kuriyan J. . 1997 Nature 385: 602–607.
Sideras P and Smith CI. . 1995 Adv. Immun. 59: 135–223.
Songyang Z, Shoelson SE, McGlade J, Olivier P, Pawson T, Bustelo XR, Barbacid M, Sabe H, Hanafusa H, Yi T, Ren R, Baltimore D, Ratnofsky S, Feldman RA and Cantley LC. . 1994 Mol. Cell. Biol. 14: 2777–2785.
Waksman G, Shoelson SE, Pant N, Cowburn D and Kuriyan J. . 1993 Cell 72: 779–790.
Weil R and Veillette A. . 1994 J. Biol. Chem. 269: 22830–22838.
Xu W, Doshi A, Lei M, Eck MJ and Harrison SC. . 1999 Mol. Cell 3: 629–638.
Xu W, Harrison SC and Eck M. . 1997 Nature 385: 595–602.
Yamaguchi H and Hendrickson W. . 1996 Nature 384: 484–489.
Zheng J, Knighton DR, Eyeck LFT, Karlsson R, Xuong N-H, Taylor SS and Sowadski JM. . 1993 Biochemistry 32: 2154–2161.
Acknowledgements
We are grateful to Chris Rudd for generously providing the polyclonal anti-Lck sera. We would also like to thank Toni Jun, Fred King, Paul Rose, Kathryn Campbell and Mike Eck for their helpful discussions during the completion of this work and Joanne Chan, Ole Gjoerup, Joan Brugge, and Sugata Sarkar for their critical reading of the manuscript. This work was supported by a National Institutes of Health Grant CA43803-10 (TM Roberts).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Laham, L., Mukhopadhyay, N. & Roberts, T. The activation loop in Lck regulates oncogenic potential by inhibiting basal kinase activity and restricting substrate specificity. Oncogene 19, 3961–3970 (2000). https://doi.org/10.1038/sj.onc.1203738
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203738
Keywords
This article is cited by
-
Predictive Model of Lymphocyte-Specific Protein Tyrosine Kinase (LCK) Autoregulation
Cellular and Molecular Bioengineering (2016)
-
Conformational states of the kinase Lck regulate clustering in early T cell signaling
Nature Immunology (2013)